top of page

News
September 2026
As part of BiotechTV’s tour of the Basel Area biotech ecosystem, our CEO Andrea Chicca discussed Synendos’ approach to restoring balance in the brain’s endocannabinoid system and our clinical progress in anxiety disorders. Watch the full interview:
May 2026
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
September 2025
Dr. Andrea Chicca, CEO, shares the highly promising results from Synendos Phase 1 Trials
September 2025
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials
July 2025
Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy
bottom of page